π Exciting Collaboration Announcement! π
April 28, 2025
We at
Pharmidex have been delighted to collaborate closely with the talented teams at
Apeikon Therapeutics and
King's College London to generate exciting new data in the field of oncology research.
We are proud to share that our collaborative poster will be presented this afternoon at the AACR Annual Meeting 2025 in Chicago! πΊπΈβ¨
π Check out the poster and learn more here:
https://lnkd.in/e7-TVBB9
A huge thank you to everyone involved for making this project a success, we are looking forward to continuing to push the boundaries of discovery together!
If you're attending AACR, come and visit, we would love to discuss our findings and explore new opportunities for collaboration.
#Pharmidex #AACR2025 #Collaboration #OncologyResearch #DrugDiscovery #TranslationalResearch #Teamwork #Innovation
We are delighted to announce and congratulate Ash Alavijeh on his appointment as Chief Operating Officer at Pharmidex . Ash has been an integral part of Pharmidex’s journey, bringing strong leadership, strategic vision and a deep commitment to advancing our capabilities in drug discovery and development. In his new role as COO, he will play a key part in driving operational excellence and supporting the continued growth of the company. This appointment reflects both Ash’s contributions to date and our confidence in his leadership as we continue to expand and evolve. Please join us in congratulating Ash on this well-deserved achievement.
Asthma affects over 260 million people worldwide and remains a significant unmet medical need. At Pharmidex , we are proud to support the development of next-generation respiratory therapies through: In vivo respiratory disease models Whole Body Plethysmography (WBP) for functional readouts Integrated PK/PD and bioanalysis Our focus is simple: generate high-quality data that enables confident decision-making and accelerates progress for patients. Because behind every dataset is a patient waiting to breathe easier.
Early-stage innovators based in Scotland have access to a significant opportunity to advance their programs toward ProofOfConcept, with an additional £2.85M fund from the Scottish Government aimed at supporting early development and enabling further investment. ποΈ Deadline: 8th May At Pharmidex , we work alongside our partners to generate robust, translational data that supports confident decision-making across early discovery and preclinical development. Our capabilities include: TargetExpression ModeOfActionStudies TargetEngagement HitIdentification ADME and PK profiling If you are preparing an application and require scientific input or timely quotations, we would be pleased to support your programme. π https://lnkd.in/eZ6vVjgN
